KOD

Kodiak Sciences Inc

3.19 USD

Last updated Dec 9, 15:48 UTC

Yesterday HIGH

$3.36

Yesterday LOW

$2.97

52w HIGH

$9.8

52w LOW

$1.37

EPS

-0.95

PE

-3.36

Next Earnings

Mar 26, 2024

Overview News Government Trades

Kodiak Sciences Inc stock is up 74.32% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November. 100% of analysts rate it a buy.

Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) The company was formerly known as Oligasis, LLC.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

kodiak.com

Benzinga Insights

Thu Jul 27, 2023

Expert Ratings for Kodiak Sciences
Benzinga Insights

Thu Jul 27, 2023

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
richadhand@benzinga.com

Thu Jul 27, 2023

UBS Downgrades Kodiak Sciences to Neutral, Lowers Price Target to $4

UBS analyst Eliana Merle downgrades Kodiak Sciences (NASDAQ:KOD) from Buy to Neutral and lowers the price target from $15 to $4.
Nabaparna Bhattacharya

Tue Jul 25, 2023

Kodiak Sciences Faces Downgrade Following Failed GLEAM And GLIMMER Studies

Chardan Global Insights analyst Daniil Gataulin downgraded the Kodiak Sciences Inc (NASDAQ: KOD)
Benzinga Insights

Tue Jul 25, 2023

Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
richadhand@benzinga.com

Tue Jul 25, 2023

Chardan Capital Downgrades Kodiak Sciences to Neutral

Chardan Capital analyst Daniil Gataulin downgrades Kodiak Sciences (NASDAQ:KOD) from Buy to Neutral.
jenniferd'souza@benzinga.com

Tue Jul 25, 2023

Barclays Maintains Underweight on Kodiak Sciences, Lowers Price Target to $2

Barclays analyst Gena Wang maintains Kodiak Sciences (NASDAQ:KOD) with a Underweight and lowers the price target from $5 to $2.
richadhand@benzinga.com

Tue Jul 25, 2023

JP Morgan Downgrades Kodiak Sciences to Underweight

JP Morgan analyst Anupam Rama downgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Underweight.
Benzinga Insights

Mon Jul 24, 2023

Stocks That Hit 52-Week Lows On Monday

On Monday, 70 companies achieved new lows for the year.
Lisa Levin

Mon Jul 24, 2023

Nasdaq Edges Higher; Applied Digital Shares Jump

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Monday. The Dow traded up 0.50% to 35,404.68 while the NASDAQ rose 0.07% to 14,043.11. The S&P 500, also rose, gaining, 0.33% to 4,551.17.